Boston Scientific, US1011371077

Boston Scientific stock: Board names Wichmann lead director in 2027

Published on 11/18/2026 at 16:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Boston Scientific stock is in focus as David S. Wichmann is set to lead the independent directors. New plans tie pay to sales, EPS and quality.

Governance and pay metrics

  • David S. Wichmann will succeed Edward J. Ludwig as Lead Independent Director.
  • The incentive plans link executive pay to global sales, adjusted earnings per share, quality and longer-term shareholder returns.
  • Performance-share programs cover relative shareholder returns and organic net sales growth.
Boston Scientific, US1011371077, Illustration mit AI erstellt.

Boston Scientific's board appointed David S. Wichmann as Lead Independent Director on November 17, 2026, with the change taking effect on January 1, 2027. The appointment and related compensation decisions were disclosed in the company's Form 8-K, according to the SEC filing.

Wichmann will succeed Edward J. Ludwig, who has held the lead independent role since 2016 and will remain on the board. Wichmann has served as a director since 2021, chairs the Audit Committee and sits on the Risk, Science and Technology Committee.

Incentives tied to execution

The board also approved the 2027 Annual Bonus Plan. It links company performance to global sales and adjusted earnings per share, while allowing the board to reduce the applicable payout percentage based on quality objectives and the performance of Boston Scientific's quality systems. Individual awards can reach 225% of target after performance modifiers.

Two performance-share programs cover the period from January 1, 2027, through December 31, 2029. One measures the company's total shareholder return against companies in the S&P 500 Healthcare Index. The other measures organic net sales growth against the company's financial plan and excludes foreign-exchange effects and certain acquisitions and divestitures without a full comparable sales period.

Stock move since the earlier report

Boston Scientific stock traded at 39.73 euros on Lang & Schwarz at 16:06 CET on Wednesday, November 18. That was 2.80% above the 39.18-euro quote reported at 13:05 CET in the earlier report, separating the intraday move from the board announcement.

Boston Scientific Corporation

  • ISIN: US1011371077
  • Ticker: BSX
  • Primary exchange: New York Stock Exchange
  • Latest quote: 39.73 euros on Lang & Schwarz, Wednesday, November 18, 2026, 16:06 CET
  • Sector: Healthcare
  • Industry: Medical devices

Current market reports provide the broader US equity context through Current market reports.

More news and analyses on Boston Scientific stock

Disclaimer...
en | US1011371077 | BOSTON SCIENTIFIC | boerse | 70531465 | bgmi